Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan,Inmaculada Rioja,Kathy Knezevic,Matthew J Bell,Miriam M Yeung,Nicola R Harker,Enid Y N Lam,Chun-Wa Chung,Paul Bamborough,Massimo Petretich,Marjeta Urh,Stephen J Atkinson,Anna K Bassil,Emma J Roberts,Dane Vassiliadis,Marian L Burr,Alex G S Preston,Christopher Wellaway,Thilo Werner,James R Gray,Anne-Marie Michon,Thomas Gobbetti,Vinod Kumar,Peter E Soden,Andrea Haynes,Johanna Vappiani,David F Tough,Simon Taylor,Sarah-Jane Dawson,Marcus Bantscheff,Matthew Lindon,Gerard Drewes,Emmanuel H Demont,Danette L Daniels,Paola Grandi,Rab K Prinjha,Mark A Dawson,Matthew J. Bell,Miriam M. Yeung,Nicola R. Harker,Enid Y. N. Lam,Chun-wa Chung,Stephen J. Atkinson,Anna K. Bassil,Emma J. Roberts,Marian L. Burr,Alex G. S. Preston,James R. Gray,Peter E. Soden,David F. Tough,Emmanuel H. Demont,Danette L. Daniels,Rab K. Prinjha,Mark A. Dawson
DOI: https://doi.org/10.1126/science.aaz8455
IF: 56.9
2020-04-24
Science
Abstract:Bromodomain inhibitors revisited Bromodomain and extraterminal domain (BET) proteins contribute to the pathogenesis of cancer and immune diseases through their effects on transcriptional regulation. BET proteins contain two nearly identical bromodomains, BD1 and BD2, structural modules that have attracted great interest as targets for drug development. First-generation drugs that inhibited both BD1 and BD2 showed promising therapeutic activity in preclinical models but proved to be less efficacious in clinical trials. Gilan et al. took a different approach and designed drugs that selectively inhibited BD1 or BD2 (see the Perspective by Filippakopoulos and Knapp). They found that BD1 and BD2 inhibitors altered gene expression in different ways and that BD2 inhibitors had greater therapeutic activity than BD1 inhibitors in preclinical models of inflammation and autoimmune disease. Science , this issue p. 387 ; see also p. 367
multidisciplinary sciences